作者
Mayumi Endo, Fadi Nabhan, Kyle Porter, Katie Roll, Lawrence A Shirley, Irina Azaryan, Dena Tonkovich, Jeanette Perlick, Laura E Ryan, Raheela Khawaja, Shumei Meng, John E Phay, Matthew D Ringel, Jennifer A Sipos
发表日期
2019/8/1
期刊
Thyroid
卷号
29
期号
8
页码范围
1115-1124
出版商
Mary Ann Liebert, Inc., publishers
简介
Background: The Afirma Gene Expression Classifier (GEC) has been used to further characterize cytologically indeterminate (cyto-I) thyroid nodules into either benign or suspicious categories. However, its relatively low positive predictive value (PPV) limited its use as a classifier for patients with suspicious results. The Afirma Gene Sequencing Classifier (GSC) was developed to improve PPV while maintaining a high negative predictive value (NPV), yet real-world assessment of its performance is lacking.
Methods: We analyzed all patients who had cyto-I nodules and molecular testing with either GEC or GSC between 2011 and 2018 at a single academic medical center. Clinical information was obtained for 343 GEC-tested nodules and 164 GSC-tested nodules.
Results: The GSC had a statistically significant higher benign call rate (76.2% vs. 48.1%, p < 0.001), PPV (60.0% vs. 33.3%, p = 0.01), and specificity …
学术搜索中的文章
M Endo, F Nabhan, K Porter, K Roll, LA Shirley… - Thyroid, 2019